In the current study, we explored the direct effects of thioridazine on anti-tumor and anti-angiogenic activity that could target the VEGFR-2/PI3K/mTOR signal transduction in ovarian tumor xenografts in vivo. As expected, the volume of thioridazine-treated tumors was 70% less than those of the controls. This evidence concerns the gene MTOR and ovarian neoplasm.